Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Search
  1. OncologyPRO
  2. Meeting resources
  3. ESMO 2016

The impact of mass spectrometry multigenic platform on the management of metastatic colorectal patients

Date

08 Oct 2016

Session

Poster Display

Presenters

Annarita Destro

Citation

Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370

Authors

A. Destro1, C. Lo Russo1, P. Spaggiari1, S. Armenia1, E. Bellofiore1, M. Lorini1, T. Brambilla1, M.M. Cimino2, A. Spinelli3, N. Personeni4, L. Rimassa4, L. Di Tommaso1, M. Roncalli1

Author affiliations

  • 1 Pathology, Istituto Clinico Humanitas, 20089 - Rozzano/IT
  • 2 Hepatobiliary Surgery, Istituto Clinico Humanitas, 20089 - Rozzano/IT
  • 3 Colorectal Surgery, Istituto Clinico Humanitas, 20089 - Rozzano/IT
  • 4 Oncology, Istituto Clinico Humanitas, 20089 - Rozzano/IT
More

Resources

Login

Abstract 2283

Background

Molecular testing is becoming an important part of the diagnosis of any patient with cancer. The challenge to laboratories is to meet this need, using reliable methods and processes to ensure that patients receive a timely and accurate report on which their treatment will be based. The aim of this abstract is to analyzed the benefit of the introduction in the clinical practice of a multigenic platform on the management of metastatic colorectal cancer (CRC).

Methods

DNA extraction by BiOstic Tissue DNA Isolation kit from tumor after microdissection (>20% tumoral cells). k-ras exon 2 mutations by Sanger sequencing in 277 CRC, by pyrosequencing (KRAS status, Diatech Pharmacogenetics) in 538 CRC; n-ras and b-raf mutations by pyrosequencing (NRAS and BRAF status, Diatech Pharmacogenetics) only in k-ras wt CRC from 01/2014. K-ras, n-ras, b-raf and pik3ca mutations by Maldi-TOF Mass Spectrometry (MassArray Agena Bioscence) with Myriapod Colon Status (Diatech Pharmacogenetics) in 170 CRC.

Results

The mutations frequencies were 41.5% k-ras by Sanger sequencing; 46.1% k-ras, 4.0% n-ras and 5.3% b-raf by pyrosequencing; 47.6% k-ras, 8.2% n-ras, 7.1% b-raf, 12.3% pik3ca by MassArray. For all genes the change of methodology has improved the diagnostic sensitivity of test. The introduction of multigenic platform allowed the simultaneous analysis of k-ras, n-ras, b-raf and pik3ca mutations in all patients with CRC, avoiding the step by step analysis approach constrained by a single gene methodology. The comparison of technical features is listed in the table.

Sanger Sequencing** Pyrosequencing MassArray
Amount of DNA 200 ng 350 ng 160 ng
Contamination Likely Possible Rare
Analytical Sensitivity 10-20% 5-7.5% 2.5-5% (b-raf 10%)
Specificity 100% 100% 100%
Consumable cost/patient* 50 euro 400 euro 200 euro
Hands-on time 4 h 4h 2.5 h
Overall time to results from the DNA 2.5 days 2.5 days 1 day
Difficulties of data interpretation Intermediate Intermediate Low
CE/IVD Validation No Yes Yes

* Cost determined on the basis of 5 patients/run. **Only k-ras exon 2

Conclusions

The introduction in the routine diagnostics of a multigenic platform is clearly an attractive approach to increase the quality and the rapidity of molecular analysis results, that can be translate in a better clinical management of metastatic colorectal patient.

Clinical trial identification

Legal entity responsible for the study

Humanitas Research Hospital

Funding

National Health System

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings